- Home
- TJX vs ABBV Comparison
TJX vs ABBV Comparison
Compare TJX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJX | ABBV |
|---|---|---|
| Founded | 1962 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.8B | 358.5B |
| IPO Year | 1994 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TJX | ABBV |
|---|---|---|
| Price | $152.14 | $249.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 18 |
| Target Price | $169.00 | ★ $253.71 |
| AVG Volume (30 Days) | 3.5M | ★ 3.8M |
| Earning Date | 05-20-2026 | 04-29-2026 |
| Dividend Yield | 1.23% | ★ 3.39% |
| EPS Growth | ★ 14.32 | N/A |
| EPS | 1.19 | ★ 2.42 |
| Revenue | $29,078,407,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $6.75 | $11.87 |
| Revenue Next Year | $5.81 | $8.12 |
| P/E Ratio | $129.24 | ★ $103.85 |
| Revenue Growth | 6.04 | ★ 8.57 |
| 52 Week Low | $132.63 | $190.75 |
| 52 Week High | $170.00 | $267.47 |
Technical Indicators
Market Signals| Indicator | TJX | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 51.81 |
| Support Level | $152.54 | $242.14 |
| Resistance Level | $157.27 | $263.35 |
| Average True Range (ATR) | 2.95 | 5.83 |
| MACD | -0.67 | -0.91 |
| Stochastic Oscillator | 9.81 | 33.76 |
Price Performance
Historical ComparisonAbout TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.